ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of ABT-888 when given in
combination with temozolomide in treating young patients with recurrent or refractory CNS
tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving ABT-888 together with temozolomide may kill more tumor cells.